Continuous Bioprocessing Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034
Page: 215 | Report Code: LS241023 | Research Suite: Report (PDF) & Market Data (Excel)
Continuous bioprocessing is a bioprocessing manufacturing
strategy in which biological production activities are carried out continuously
instead of in discrete batches. This technique allows materials to move through
the production process without interruption, which is able to enhance
productivity and cut down on processing times and operating expenses.
MARKET
OVERVIEW
The continuous bioprocessing market is valued at approximately USD 218 million in 2023 and is projected to reach USD 2013.97 million by 2034 exhibiting a compound annual growth rate (CAGR) of 22.4% during the forecast period of 2024-2034. Continuous bioprocessing maximizes resource utilization and reduces waste by fusing upstream and downstream processes into a smooth workflow.
GROWTH
DRIVERS
The market for continuous bioprocessing is primarily influenced
by the rising demand for biopharmaceuticals. Biologics, which are capable of
targeting particular diseases with fewer side effects than traditional
medications, are becoming increasingly more necessary as the healthcare
environment changes. For instance, the use of monoclonal antibodies (mAbs) is
increasingly becoming popular due to their effectiveness in treating chronic
diseases such as cancer and autoimmune disorders. According to the U.S. FDA
report, biologics accounted for 40.5% of all authorized medications in 2022,
demonstrating a strong trend toward biopharmaceuticals.
Continuous bioprocessing has a number of benefits over
fed-batch or batch processing techniques. These advantages include increased
productivity, better product uniformity, and less downtime in between
manufacturing cycles. For example, continuous flow production is able to
improve product uniformity across batches, decrease buffer usage, and cut
manufacturing costs. Due to its operational efficiency, continuous
bioprocessing is a desirable and popular alternative for manufacturing
companies seeking to streamline their manufacturing processes.
The continuous bioprocessing market’s growth is further
fueled by the emergence of integrated end-to-end solutions, technological
advancements, regulatory support promoting adoption, and a focus on cost reduction.
MARKET
SEGMENTATION:
By Product
-
·
Chromatography Systems and Consumables
·
Filtration Systems and Devices
·
Bioreactors
·
Consumables
o Cell
Culture Media & Buffers
o Reagents
·
Other Products
By Scale
of Operation -
·
Commercial Operations
·
Clinical Operations
By
Process -
·
Downstream Process
·
Upstream Process
By
Application -
·
Monoclonal Antibodies
·
Vaccines
·
Cell & Gene Therapy
·
Other Applications
By End
User -
·
Pharmaceutical & Biotechnology
Companies
·
Contract Research Organizations (CROs)
and Contract Manufacturing Organizations (CMOs)
·
Academic & Research Institutes
By
Region -
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East and Africa
Continuous
Bioprocessing Market By Product Segment Review:
The segment of filtration systems and devices dominated the global market for continuous bioprocessing. The market demand of this segment is growing due to the growing emphasis on process efficiency and product quality assurance within biomanufacturing environments.
Continuous
Bioprocessing Market By Scale of Operation Segment Review:
Commercial operations are large-scale manufacturing
procedures designed to produce biopharmaceuticals in significant quantities
that are prepared for distribution on the market. In order to maintain
regulatory compliance and maximize output, the commercial segment is
distinguished by large investments in technology and infrastructure.
Continuous
Bioprocessing Market By Process Segment Review:
The downstream process of continuous bioprocessing
encompasses the stages that occur following the biologic production of a
desired product, such as proteins, enzymes, or other biomolecules. The downstream
segment is growing due to the increased demand for high-purity
biopharmaceuticals and advancements in purification technologies that allow for
more efficient processing.
Continuous
Bioprocessing Market By Application Segment Review:
Modern biopharmaceuticals rely heavily on monoclonal
antibodies (mAbs). Monoclonal antibodies are in high demand worldwide because
of their ability to treat a wide range of diseases, especially autoimmune
diseases and cancers.
Continuous
Bioprocessing Market By End User Segment Review:
The pharmaceutical and biotechnology sectors are the major
end user in the continuous bioprocessing market. The demand for
biopharmaceuticals is on the rise in the pharmaceutical and biotechnology
sectors due to their effectiveness in treating chronic diseases and conditions
such as cancer, autoimmune disorders, and infectious diseases.
Continuous
Bioprocessing Market By Region Segment Review:
The North America region is anticipated to hold the largest market
share for continuous bioprocessing due to the well-established
biopharmaceutical industry, and significant investment in research and
development. The Asia Pacific market is anticipated to grow rapidly during the
forecast period due to region’s increasing investments in biotechnology and
pharmaceuticals.
Continuous
Bioprocessing Market Regional Synopsis:
North America is expected to dominate the continuous bioprocessing
market due to region’s well-established biopharmaceutical manufacturing base,
and numerous government initiatives aimed at supporting its adoption.
Europe is another well-established player in continuous
bioprocessing market. It is growing due to region’s strong regulatory support
and increasing investment in research and development for biologics.
The Asia Pacific market is expected to grow at the maximum
rate during the forecast period due to their rapid industrialization, various
government initiatives, and increasing investments in biotechnology and
pharmaceuticals.
The market in Latin America is growing due to the rising
prevalence of chronic diseases, which is driving the demand for biologics. The
growth of this market is expected to further impacted by government initiatives
supporting biotechnology development, and technological advancements
facilitating efficient production processes.
The Middle East & African market is witnessing growth potential due to surge in investments aimed at developing novel biologics, advanced therapies, and personalized medicine.
Continuous
Bioprocessing Market Key Challenges:
The cost of initial setup for continuous bioprocessing is
significant because of the need for advanced equipment such as specialized
bioreactors, chromatography systems, and automation technologies. The high capital
requirements often make it particularly challenging for smaller players in the
market to enter. The requirement for economic research before purchasing
continuous production equipment is likely to deter prospective manufacturers
that lack the necessary funds or resources.
The complex processes involved in continuous bioprocessing
necessitate the real-time monitoring and management of numerous crucial
parameters and quality features. The integration of upstream and downstream
processes in a continuous mode is complex and presents various challenges. For
instance, while batch processing is generally considered less complicated,
continuous systems require advanced technologies like sophisticated automation
and process control technologies to effectively manage the flow of materials.
This complexity increases the risks of failure if not managed properly.
Continuous
Bioprocessing Market Competitive Landscape:
The global market for Continuous Bioprocessing is
characterized by a mix of established companies and emerging firms, each
striving to enhance their competitive edge.
The primary focus of key players in this market is on
developing and providing advanced technologies and solutions that improve
efficiency and effectiveness of biopharmaceutical manufacturing processes. They
often establish strategic partnerships and collaborations to improve their
product offerings and reaching a wider audience. For instance, in August 2023,
Sartorius collaborated with Repligen Corporation to launch integrated bioreactor
system that integrates Repligen XCell® ATF upstream intensification technology
into Sartorius’ Biostat STR® bioreactor to simplify the process of intensified
seed train and N perfusion implementation for biopharmaceutical manufacturers.
Continuous
Bioprocessing Market Key Players:
·
3M
·
Repligen Corporation
·
Bionet
·
Sartorius AG
·
Thermo Fisher Scientific Inc.
·
WuXi Biologics
·
Corning Incorporated
·
Integris
·
Esco Lifesciences Group
·
Getinge AB
·
Other Key & Niche Players